Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism
Receptor activator of nuclear factor kappa B (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are members of the tumour necrosis factor receptor super family and play a pivotal role in bone remodelling. RANKL binds to RANK on the surface of osteoclastic precursors and thereby enhances the di erentiation and activity of osteoclasts and inhibits their apoptosis [1] .
e e ects of RANKL are counteracted by OPG, which functions as a neutralizing decoy receptor.
Animal model and cell culture studies suggest a direct inhibitory e ect of androgens on the OPG/RANKL cytokines system. In human osteoblastic cells, androgen receptor-induced speci c inhibition of OPG mRNA expression by both testosterone and 5α-dihydrotestosterone has been reported [2, 3] . Androgens have also been shown to block RANKL-induced osteoclastic formation [4, 5] while RANKL expression was found to be up-regulated in osteoblastic cells from androgen receptor-de cient mice [6] . In the rat, orchiectomy was associated with increased bone marrow-free soluble RANKL levels [7] and, notably, RANKL inhibition prevented orchiectomyrelated bone loss [8] , thus supporting the hypothesis that ampli ed RANKL activity promotes bone loss in androgende ciency states. In gonadotropin releasing hormone-induced male hypogonadism, testosterone replacement therapy signicantly decreased serum OPG levels [9] while low serum OPG was observed in women with polycystic ovary syndrome [10] , a disorder characterized by hyperandrogenemia.
Information on circulating OPG and RANKL changes is scarce in male hypogonadism and most studies originate from men under androgen-deprivation therapy for prostate malignancy. In an attempt to characterize the OPG/RANKL cytokines status in a naturally occurring model of androgen insuciency, serum OPG/soluble RANKL levels were determined in elderly men with and without hypogonadism who tested negative at prostate cancer screening, and the relationships among these molecules and both sex hormones levels and bone remodelling parameters were analysed.
Methods

Study subjects
Eighty-one men aged ≥50 years entered this case-control study. According to ISA, ISSAM, EAU, EAA and ASA recommendations [11] , late-onset hypogonadism (LOH) was diagnosed in 39 men aged 70.25 ± 1.26 years based upon loss of libido and/ or erectile dysfunction and serum total testosterone (TT) <350 ng/dl and/or low calculated serum free testosterone; 42 age-matched men (68.45 ± 1.23 years) with normal basal hypothalamus-pituitary-testicular function were used as controls. Secondary causes of hypogonadism, hyperprolactinemia, advanced chronic renal failure and diabetes mellitus were exclusion criteria. Men with suspected prostate cancer, assessed by elevated prostate-speci c antigen (PSA) levels, with or without abnormal histology in prostate biopsy samples, were not included. e study was done with approval of the local ethics committee and informed consent was given by all participants.
Serum assays
Fasting blood samples were collected from each patient. Serum total testosterone (TT), sex hormone-binding globulin (SHBG), estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), OPG and total soluble RANKL (sRANKL) were concomitantly assessed in all participants by ELISA (DRG Instruments GmbH, Marburg, Germany). C-terminal telopeptide of type I collagen (β-Cross Laps ® , CTx) and bone-speci c alkaline phosphatase (Ostase ® , BAP) were measured by ELISA from Immunodiagnostic Systems Ltd, Boldon, UK). Free testosterone (FT) concentration was calculated according to Vermeulen's formula [12] and cuto levels of 225 pmol/l were considered to de ne hypogonadism [11] . e intra-assay and inter-assay coe cients of variance (CV) were 4.4% and 5.7% for OPG and 4.6% and 9.1% for sRANKL, respectively. e sensitivity of the serum OPG assay was less than 0.14 pmol/l whereas the lowest detectable concentration of total sRANKL was 10 pmol/l.
Statistical analysis
Descriptive results are presented as mean ± S.E.M. One-way ANOVA or Kruskal-Wallis tests were used to test for di erences between groups, as appropriate. Correlation analysis among continuous variables was performed, quantifying the strength of the associations by calculating either the simple or partial Pearson's correlation coe cient or the non-parametric Spearman's rank correlation coe cient. e stepwise multiple regression analysis was used to determine which variables predict serum OPG or RANKL levels. In all statistical tests performed, a p-value of < 0.05 was considered as statistically signi cant.
Results
Endocrine parameters of the pituitary-testicular axis and markers of bone turnover measured in both study groups are presented in Table 1 . Compared with controls, LOH men had signi cantly lower TT, FT and E 2 levels but higher bone turnover rate. Serum PRL values for hypogonadal men were within Serum OPG levels were positively related to age, whereas sRANKL levels were not (Table 2) . Cross-sectional analysis of serum OPG and sRANKL levels revealed signi cantly higher levels of both in men with LOH compared with controls ( Fig.   1a, b) . When sRANKL/OPG was considered, no signi cant di erence was seen between hypogonadal men and controls (p = 0.289).
As depicted in Table 2 , serum OPG was signi cantly and inversely associated with FT in simple and age-adjusted analysis (r = -0.244, p = 0.029) and positively with SHBG (r = 0.338, p = 0.002 in age-adjusted analysis) and E2 (r = 0.274, p = 0.014 in age-adjusted analysis). Soluble RANKL showed only a tendency towards a negative correlation to FT while no relationship whatsoever was seen with serum E 2 ( Table 2) . Both cytokines were signi cantly and positively associated with serum LH levels ( 0.074, p = 0.520 for OPG and r = 0.209, p = 0.084 for RANKL). Furthermore, the relationship between OPG/ RANKL and bone turnover was analyzed (Table 2) . It was observed that serum OPG was directly related to BAP levels in simple and age-adjusted analysis (r = 0.270, p = 0.015) and CTx concentration (r = 0.192, p = 0.088 a er controlling for age). In contrast, no statistically signi cant relationship between sRANKL and either BAP or CTx was found.
Multiple regression analysis in a stepwise model applied to the study population of elderly men, with OPG as a dependent variable and age and markers of bone turnover as independent variables (R 2 = 0.157, F-ratio = 7.304, p = 0.001), revealed age (beta = 0.302, p = 0.004) and BAP (beta = 0.257, p = 0.015) as signi cant determinants of OPG levels, with the above mentioned predictors explaining 13.61% of OPG variability. Adding SHBG and sex steroids as independent variables improved the model (R 2 = 0.313, F-ratio = 8.664, p < 0.001), explaining 27.71% of the variation in OPG concentration. Age (beta = 0.302, p = 0.001), SHBG (beta = 0.337, p = 0.002), E 2 (beta = 0.226, p = 0.012) and BAP (beta = 0.257, p = 0.015) were further retained as independent predictors of OPG. None of endocrine or bone metabolism variables was found to independently predict serum sRANKL concentration in this study.
Discussion
In the present study, it is shown that men with LOH have elevated circulating OPG and sRANKL levels in comparison with age-matched men exhibiting normal pituitary-testicular function. ere is lack of convincing evidence that serum levels of these cytokines adequately re ect the protein activity in the skeleton [1, 13] ; nevertheless, these ndings support the hypothesis that androgens act either directly or indirectly to suppress OPG/RANKL activity in human bone. In agreement with these results, increased skeletal expression of both RANKL and OPG genes has been found in the orchiectomized rat [14] and high bone marrow RANKL levels have also been demonstrated 7 . Moreover, RANKL-mediated, osteoclastinduced bone resorption can be prevented in the animal rat model by testosterone undecanoate therapy 7 or by osteoprotegerin infusion [8] , suggesting that an increased functional RANKL/OPG ratio is associated with male hypogonadism by promoting bone loss.
A link between the OPG/RANKL system and circulating sex steroids in elderly men is evidenced by the close relationship among TT, FT and E2 concentrations on one hand and serum OPG on the other hand. e present study con rms the ndings of Gannagé-Yared [15] and Khosla et al. [16] that show an inverse relationship between OPG and the free androgen index or bio-available testosterone, respectively, in men over 50 but is contrast to the results of Oh et al. that show no relationship between OPG and total testosterone in middleaged males [17] or to those of Szulc et al. that describe a positive correlation between OPG and both the free androgen index and the free estradiol index in men aged 19-85 years [18] . Nonetheless, total, but not free, testosterone was evaluated in some studies in which no relationship was seen between OPG and androgens [17] . Moreover, this study demonstrates that both OPG and sRANKL are signi cantly correlated with serum LH levels -an independent indicator of low FT in older men [19] . As shown in a previous study [15] , OPG and SHBG are positively related in aging men. Moreover, SHBG independently predicts serum OPG in stepwise multiple regression analysis, suggesting that an age-related increase in SHBG may account not only for the lower FT [19] levels but also for the signi cantly higher circulating OPG levels in hypogonadal older men. e positive correlation between OPG and markers of bone remodeling in the ageing male population from our study is in line with the hypothesis that the increased OPG levels indicate a protective mechanism for counteracting the bone loss induced by accelerated RANKL-mediated bone resorption. Furthermore, in primary cell cultures of human osteoblasts, it has been shown that OPG directly increases alkaline phosphatase production and in vitro mineralization, and that all OPG-mediated e ects can be prevented by RANKL neutralizing antibodies [13] . Presumably, compensatory increased OPG acts by stimulating osteoblasts, thus coupling bone resorption to bone formation.
In multiple regression analysis with variables tted in a forward stepwise manner, serum OPG has been shown to be independently predicted by BAP, a solid formation marker.
us, irrespective of the underlying pathological process, accelerated bone turnover may act as a determining condition of high OPG in elderly men. Power analysis for multiple regression showed that the sample size used in this model resulted in a high statistical power of >0.9 to detect signi cant interaction between predictors in multiple regression.
Studies of the association between serum RANKL and sex steroids are even less consistent than those of OPG, with most studies not revealing any relationship between these two parameters in men [17, 20] . Taking into account the higher serum sRANKL level in the hypogonadal group, as well as the inverse correlation between sRANKL and LH, RANKL appears to intervene to promote bone loss associated with LOH. In clinical studies, few reported any interrelations between RANKL and markers of bone turnover in presumably healthy men [17] and most failed to obtain any consistent conclusion. Nevertheless, this might be due to circulating RANKL re ecting suboptimal skeletal expression of RANKL; in agreement with this theory, association studies have clearly shown that skeletal RANKL messenger RNA levels are signi cantly linked to histomorphometric bone resorption indices in both normal human cancellous bone 21 and metabolic bone disease [22] .
Moreover, agents with the potential to block RANKL e ects in the skeleton have emerged as therapeutic tools in postmenopausal or glucocorticoid-induced osteoporosis [23] or malignancy-related bone disease [24] . Data showing favorable results with denosumab, a recently developed anti-RANKL monoclonal antibody that reduces the incidence of vertebral fractures in men with non-metastatic prostate cancer receiving androgen-deprivation therapy [25] , also suggest potential use of denosumab as a therapeutic tool in endogenous hypogonadism-related male osteoporosis.
ere are two limitations that need to be addressed regarding the present study. e rst limitation concerns the relatively small sample size of participants. Second, the lack of information on bone mineral density (BMD) status for study subjects may hinder a deeper understanding of the relevance of the circulating OPG/RANKL changes to LOH-dependent low bone mass. Nonetheless, results from previous clinical studies, which examined the relationships between BMD, as assessed by dual X-ray absorptiometry (DXA), and serum OPG/RANKL levels in various male populations were conicting and rather inconclusive [1, [16] [17] [18] 26] . erefore, the more dynamic bone turnover parameters may better express the association between OPG/RANKL and bone status. In addition, in preclinical models, it has been shown that OPG treatment increases bone volume and also trabecular thickness and connectivity [1] , thus suggesting a role for OPG in maintaining bone architecture and thus bone quality, a parameter poorly re ected by BMD measurement.
To conclude, late-onset hypogonadism is associated to an enhanced RANKL activity suggesting a role of RANKLmediated bone resorption in androgen-de ciency induced bone loss. In turn, bone turnover-related OPG may act as a coupling factor, linking bone resorption to subsequent bone formation to maintain bone remodelling balance.
